The leading cause of disease-related death in young children and adolescents is cancer. Each year, more than 35,000 new cases of cancer are detected and more than 6,500 young people die.
Only 9 out of 150 approved cancer drugs in the past decade were specifically for children. One of the reasons is that there are no appropriate tools to test drugs for children’s cancer.
In order to combat this problem, the ITCCP4 project has developed a set of models that are specifically designed for testing drugs against paediatric tumours. These models will be made available by a non profit association at a cost.
Researchers use models to get an idea of what the body and tumours will respond like. Models are used to test the effectiveness of drugs before they can be tested on humans.
Children’s cancers are not the same as adult cancers. Children’s cancers can be more aggressive than adult cancers and act differently. The immune system of children also differs from that of adults. Therefore, testing adult models will not be sufficient.
Lou Stancato of Indiana Biosciences Research Institute, Indiana University School of Medicine and ITCC-P4 online event, held on April 24, 2025, said: “Less money has been spent developing models of children’s tumors in comparison to adult cancers. The lack of easily available models for childhood cancer was a problem.”
Models were often only available in labs of academics, and they weren’t accessible. Children were at a disadvantage because they did not have access to research tools that could identify cancer drugs.
It was the ideal environment to create models that were specific to childhood cancers and make them accessible to pharmaceutical companies through the creation of an organisation non-profit.
The goal was to develop a platform for early testing of anticancer medications on a newly developed repertoire of paediatric model systems, says Gilles Vassal. He is p.a. oncologist and chief operating officer of ITCC-P4 GmbH.
We have developed a large number of paediatric tumor models. More than 300 of these were created from tumours taken from patients. Now we represent over 20 paediatric tumours.”
The barriers for developing new drugs to treat childhood cancers have been reduced thanks to models created by ITCC P4.
Stancato says that for the first time, paediatric cancer research has been on an equal footing to what adult cancer researchers have had available since decades. By creating a diverse panel of tumor models, Stancato says that anyone could use this resource to test drugs.
Nicole Scobie’s son, who survived childhood cancer, couldn’t wait to see the results.
The need to act quickly is paramount, as children who have cancer cannot wait. ITCC-P4’s robust preclinical platform has allowed for faster identification of drug candidates that could be effective treatment for children. It’s a speeding up that may lead to a quicker release of cancer drugs for children.
Her praise also extended to ITCC-P4’s commitment to continue reinvesting any profit made in order to boost their innovation and research wing. Gilles confirms that as a not-for-profit organization, the research on new models and improvements will continue.
This isn’t the end. New tumour models could be created. To evaluate new cancer compounds, we need to develop better models. It is important to identify which organoids can help with the evaluation of a new drug. “We will continue our R&D in order to create more relevant and predictable models,” he said.
The Minister called upon the industry to recognize the opportunities presented by ITCC P4 and use the models to ensure that the new treatments are available to children sooner.
I have a strong message to the industry. Don’t lose hope in childhood cancer. This important tool was created to assist you in determining which drugs are worth pursuing, making it more effective and addressing the needs of cancer patients.
The Innovative Medicines Initiative (IMI) is a partnership of the European Union with the European Pharmaceutical Industry.
Source: Read the full original article, ITCC-P4 helps to get medicine faster to cancer patients., on the website of the Innovative Health Initiative (IHI)